NervGen rises after FDA backs late-stage study to test drug for spinal cord injury

Nervgen Pharma

07/04/2026 13:36

** Shares of biotech firm NervGen Pharma NGEN.O rise 7% to $4.71 premarket

** Co says the FDA agreed on the design of a late-stage study for its experimental drug for spinal cord injury, NVG-291,  that aims to improve hand movement in people with chronic paralysis of all four limbs

** Co says the 16-week study in about 150 adults in the U.S. and Canada will test whether daily injections improve fine hand use versus placebo

** Says the FDA alignment follows earlier results showing better hand function, bladder control and less muscle stiffness in treated patients

** Adds the trial is expected to start in mid-2026; NVG-291 already has FDA fast-track status

** As of last close, stock down ~22% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))